MAbxience expands the facilities of the León Technology Park

News about our members

April 9th 2023Members news

The biotechnology company mAbxience, from the Chemo Group (Insud Pharma), expands its facilities on the plots it owns in the León Technology Park to have more space for the production of biosimilar monoclonal antibodies.

READ MORE

recently published

Post thumb
Informative breakfasts "Study on the market of biosimilar medicines in the National Health System in Spain"
March 18 2024
Post thumb
Horizon scanning
Jan 31 2024
Post thumb
Early Treatment: the role of biosimilars
18 2023 December
Post thumb
Study on the market for biosimilar medicines in the National Health System in Spain 2016-2022
18 2023 December

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE